Cargando…
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307982/ https://www.ncbi.nlm.nih.gov/pubmed/35923562 http://dx.doi.org/10.32607/actanaturae.11611 |
_version_ | 1784752885521711104 |
---|---|
author | Bragina, O. D. Deyev, S. M. Chernov, V. I. Tolmachev, V. M. |
author_facet | Bragina, O. D. Deyev, S. M. Chernov, V. I. Tolmachev, V. M. |
author_sort | Bragina, O. D. |
collection | PubMed |
description | This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction. |
format | Online Article Text |
id | pubmed-9307982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | A.I. Gordeyev |
record_format | MEDLINE/PubMed |
spelling | pubmed-93079822022-08-02 The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer Bragina, O. D. Deyev, S. M. Chernov, V. I. Tolmachev, V. M. Acta Naturae Research Article This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction. A.I. Gordeyev 2022 /pmc/articles/PMC9307982/ /pubmed/35923562 http://dx.doi.org/10.32607/actanaturae.11611 Text en Copyright ® 2022 National Research University Higher School of Economics. https://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bragina, O. D. Deyev, S. M. Chernov, V. I. Tolmachev, V. M. The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title | The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title_full | The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title_fullStr | The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title_full_unstemmed | The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title_short | The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer |
title_sort | evolution of targeted radionuclide diagnosis of her2-positive breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307982/ https://www.ncbi.nlm.nih.gov/pubmed/35923562 http://dx.doi.org/10.32607/actanaturae.11611 |
work_keys_str_mv | AT braginaod theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT deyevsm theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT chernovvi theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT tolmachevvm theevolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT braginaod evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT deyevsm evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT chernovvi evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer AT tolmachevvm evolutionoftargetedradionuclidediagnosisofher2positivebreastcancer |